A Prospective Italian Study on Baseline NS3 and NS5A Resistance to Direct-Acting Antivirals in a Real-World Setting of HIV-1/HCV Coinfected Patients and Association with Treatment Outcome

We prospectively evaluated the frequency of natural resistance-associated substitutions (RASs) in the NS3 and NS5A regions according to different HCV genotypes and their possible effect on treatment outcome in HIV-1/HCV patients treated with direct-acting antivirals (DAAs). Baseline RASs in the NS3 and NS5A domains were investigated in 62 HIV-1/HCV patients treated with DAAs: 23 patients harbored HCV-GT1a, 26 harbored GT3a, and 13 harbored GT4d. A higher occurrence of RASs was found in the NS3 domain within GT1a (13/23) than GT3a (0/26) or GT4d (2/13). With regard to treatment outcome, NS3 RASs were detected in 14/56 patients with sustained virological response (SVR) and in 1/6 non-responder (NR) patients. Occurrence of RASs of NS5A domain was lower in SVR (4/56, had RASs) than in NR (3/6, had RASs). Evaluation of RASs at baseline instead of at virological failure, especially in the NS5A domain, could positively influence the choice of new DAA combinations for the treatment of HIV-1/HCV patients.

[1]  C. Lumbreras,et al.  Predictive factors of hepatitis C virus eradication after interferon-free therapy in HIV coinfection , 2019, European Journal of Clinical Microbiology & Infectious Diseases.

[2]  F. Ceccherini‐Silberstein,et al.  Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1–4 in Italy , 2018, Scientific Reports.

[3]  Francesca Ceccherini-Silberstein,et al.  Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018. , 2018, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[4]  V. Cuervas-Mons,et al.  Baseline NS5A resistance associated substitutions may impair DAA response in real‐world hepatitis C patients , 2018, Journal of medical virology.

[5]  K. Chayama,et al.  Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan , 2017, Antimicrobial Agents and Chemotherapy.

[6]  H. Mo,et al.  Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses. , 2017, Journal of hepatology.

[7]  G. Lauer,et al.  Analysis of resistance‐associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents , 2017, Journal of viral hepatitis.

[8]  H. Mo,et al.  Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir. , 2016, Gastroenterology.

[9]  A. Calcagno,et al.  HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testing , 2016, Infection.

[10]  V. Soriano,et al.  Hepatitis C virus resistance to the new direct-acting antivirals , 2016, Expert opinion on drug metabolism & toxicology.

[11]  H. Mo,et al.  Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein , 2016, Antimicrobial Agents and Chemotherapy.

[12]  P. Hu,et al.  Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data , 2016, Scientific Reports.

[13]  Christoph Sarrazin,et al.  The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. , 2016, Journal of hepatology.

[14]  M. Carr,et al.  Baseline Prevalence and Emergence of Protease Inhibitor Resistance Mutations following Treatment in Chronic HCV Genotype-1-Infected Individuals , 2015, Antiviral therapy.

[15]  Tara L. Kieffer,et al.  Hepatitis C virus drug resistance–associated substitutions: State of the art summary , 2015, Hepatology.

[16]  F. Mcphee,et al.  NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection , 2015, The Journal of infectious diseases.

[17]  R. Kaiser,et al.  Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors , 2015, Open forum infectious diseases.

[18]  D. Webster,et al.  Baseline drug Resistance Mutations are Detectable in HCV Genes NS3 and NS5A but not NS5B in Acute and Chronic HIV-Coinfected Patients , 2014, Antiviral therapy.

[19]  H. Walter,et al.  Appearance of NS3 Q80K mutation in HCV genotype 1a mono- or HIV/HCV co-infected patients in a Berlin laboratory , 2014, Journal of the International AIDS Society.

[20]  Xin Huang,et al.  Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS‐790052 in Humans: In Vitro and In Vivo Correlations , 2011, Hepatology.

[21]  P. Colson,et al.  Two years' persistence of naturally present substitution R155K within hepatitis C virus NS3 protease in the absence of protease inhibitor-based therapy. , 2011, The Journal of infectious diseases.